Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma

Authors:

Top Cited Papers
Open Access
Abstract
Myxoid liposarcoma is a rare cancer with an incidence of 2 per million person-years,1 representing approximately 5% of soft-tissue sarcoma (STS) in adults worldwide.2 The predominant tumor location is the extremity, although the cancer can also present primarily in the trunk or head and neck region. Myxoid liposarcoma occurs in a relatively young patient population, with a peak incidence in the fifth decade of life,2 which implies that survivors could experience late-treatment toxic effects for a long time.

This publication has 41 references indexed in Scilit: